CN Patent

CN1863774A — 用作蛋白激酶抑制剂的化合物和组合物

Assigned to IRM LLC · Expires 2006-11-15 · 20y expired

What this patent protects

本发明提供了一类新的化合物、含有这些化合物的药物组合物和使用这些化合物来治疗或预防与激酶活性异常或失调有关的疾病或病症，特别是与Abl、BCR－Abl、CSK、JNK1、JNK2、PDGF－R、p38、p70S6K、TGFβ、SRC、EGFR、c－Kit、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6和SAPK2β异常激活有关的疾病或病症的方法。

USPTO Abstract

本发明提供了一类新的化合物、含有这些化合物的药物组合物和使用这些化合物来治疗或预防与激酶活性异常或失调有关的疾病或病症，特别是与Abl、BCR－Abl、CSK、JNK1、JNK2、PDGF－R、p38、p70S6K、TGFβ、SRC、EGFR、c－Kit、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6和SAPK2β异常激活有关的疾病或病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN1863774A
Jurisdiction
CN
Classification
—
Expires
2006-11-15
Drug substance claim
No
Drug product claim
No
Assignee
IRM LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.